This is an old revision of this page, as edited by DMacks(talk | contribs) at 06:26, 30 October 2022(rm no-such-field). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:26, 30 October 2022 by DMacks(talk | contribs)(rm no-such-field)
On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee's consideration before it proceeds to the second phase of the trial.[7]
Phase II and III trials
On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with BBV154 in healthy volunteers.[8]
References
^Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at ClinicalTrials.gov